Tipranavir adverse reactions: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) (Created page with "__NOTOC__ {{Tipranavir}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = APTIVUS (TIPRANAVIR) CAPSULE, LIQUID FILLED APTI...") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AZ}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Adverse Reactions== | |||
The following adverse reactions are described, in greater detail, in other sections: | |||
*'''Hepatic Impairment and Toxicity''' | |||
*'''Intracranial Hemorrhage''' | |||
*'''Rash''' | |||
Due to the need for co-administration of APTIVUS with ritonavir, please refer to ritonavir prescribing information for ritonavir-associated adverse reactions. | |||
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = APTIVUS (TIPRANAVIR) CAPSULE, LIQUID FILLED APTIVUS (TIPRANAVIR) SOLUTION [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=08982e49-d2eb-4b25-b01a-1be52fd669ef | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 16:12, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Adverse Reactions
The following adverse reactions are described, in greater detail, in other sections:
- Hepatic Impairment and Toxicity
- Intracranial Hemorrhage
- Rash
Due to the need for co-administration of APTIVUS with ritonavir, please refer to ritonavir prescribing information for ritonavir-associated adverse reactions.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.[1]
References
Adapted from the FDA Package Insert.